Lexicon Pharmaceuticals, Inc. (LXRX)
Nasdaq · Pharmaceutical Preparations · Manufacturing · CIK 1062822 · fiscal year ends in Dec
Closing price $1.49 on 29 Oct 2026; 52-week range $1.14 to $2.64.
Key figures
The last twelve months reported, with the latest price and balance sheet.
- Revenue, last twelve months
- $41.5M
- Revenue growth
- -29.0%
- Net income, last twelve months
- -$61.1M
- Earnings per share
- -$0.15
- Gross margin
- 99.1%
- Operating margin
- -131.4%
- Net margin
- -147.4%
- Return on equity
- -35.0%
- Market value
- $665.8M
- Cash
- $40.9M
- Debt
- $51.4M
- Debt to equity
- 0.29
- Shares outstanding
- 446.9M
Financial statements
Revenue, profit and cash flow by fiscal year, each year linked to its annual report.
| Fiscal year | Year end | Revenue | Operating income | Net income | EPS | Free cash flow | Filing |
|---|---|---|---|---|---|---|---|
| FY2025 | 31 Dec 2025 | $49.8M | -$48.9M | -$50.3M | -$0.14 | -$67.9M | 10-K filed 5 Mar 2026 |
| FY2024 | 31 Dec 2024 | $31.1M | -$197.1M | -$200.4M | -$0.63 | -$179.8M | 10-K filed 7 Mar 2025 |
| FY2023 | 31 Dec 2023 | $1.2M | -$171.8M | -$177.1M | -$0.80 | -$162.4M | 10-K filed 25 Mar 2024 |
| FY2022 | 31 Dec 2022 | $139.0K | -$100.8M | -$101.9M | -$0.62 | -$90.2M | 10-K filed 3 Mar 2023 |
| FY2021 | 31 Dec 2021 | $298.0K | -$87.1M | -$87.8M | -$0.60 | -$88.2M | 10-K filed 10 Mar 2022 |
By quarter
| Quarter | Quarter end | Revenue | Net income | EPS |
|---|---|---|---|---|
| Q2 FY2026 | 30 Jun 2026 | $692.0K | -$31.8M | -$0.07 |
| Q1 FY2026 | 31 Mar 2026 | $21.1M | -$1.0M | $0.00 |
| Q4 FY2025 | 31 Dec 2025 | $5.5M | -$15.5M | -$0.04 |
| Q3 FY2025 | 30 Sep 2025 | $14.2M | -$12.8M | -$0.04 |
| Q2 FY2025 | 30 Jun 2025 | $28.9M | $3.3M | $0.01 |
| Q1 FY2025 | 31 Mar 2025 | $1.3M | -$25.3M | -$0.07 |
| Q4 FY2024 | 31 Dec 2024 | $26.6M | -$33.8M | -$0.09 |
| Q3 FY2024 | 30 Sep 2024 | $1.8M | -$64.8M | -$0.18 |
Revenue by segment
As the company reports it in the segment note of its annual report.
By product, FY2025
| Segment | Revenue | Share |
|---|---|---|
| License | $45.0M | 90.6% |
| Product | $4.6M | 9.4% |
Company events
The newest 8-K filings of 243 held.
| Filed | Form | Event | Items |
|---|---|---|---|
| 6 Aug 2026 | 8-K | Results | 2.02, 9.01 |
| 7 May 2026 | 8-K | Results | 2.02, 9.01 |
| 6 May 2026 | 8-K | Material agreement, New debt, Share sale, Investor update | 1.01, 2.03, 3.02, 7.01, 9.01 |
| 30 Apr 2026 | 8-K | Material agreement, Share sale, Shareholder vote, Bylaws or fiscal year change | 1.01, 3.02, 5.03, 5.07, 9.01 |
| 5 Mar 2026 | 8-K | Results | 2.02, 9.01 |
| 2 Feb 2026 | 8-K | Material agreement, Share sale, Shareholder rights change, Bylaws or fiscal year change, Investor update | 1.01, 3.02, 3.03, 5.03, 7.01, 9.01 |
| 29 Jan 2026 | 8-K | Results, Investor update, Other events | 2.02, 7.01, 8.01, 9.01 |
| 10 Nov 2025 | 8-K | Other events | 8.01 |
| 6 Nov 2025 | 8-K | Other events | 8.01, 9.01 |
| 6 Nov 2025 | 8-K | Results | 2.02, 9.01 |
| 6 Aug 2025 | 8-K | Results | 2.02, 9.01 |
| 28 Jul 2025 | 8-K | Other events | 8.01 |
Every filing
The newest filings with the SEC of 584 held.
| Filed | Form | Period |
|---|---|---|
| 14 Aug 2026 | EFFECT | – |
| 6 Aug 2026 | S-3 | – |
| 6 Aug 2026 | S-8 | – |
| 6 Aug 2026 | 10-Q | 30 Jun 2026 |
| 6 Aug 2026 | 8-K | 6 Aug 2026 |
| 7 May 2026 | 10-Q | 31 Mar 2026 |
| 7 May 2026 | 8-K | 7 May 2026 |
| 6 May 2026 | 8-K | 4 May 2026 |
| 30 Apr 2026 | 8-K | 30 Apr 2026 |
| 16 Mar 2026 | ARS | 31 Dec 2025 |
| 16 Mar 2026 | DEFA14A | – |
| 16 Mar 2026 | DEF 14A | 16 Mar 2026 |
Insider trades
Form 4 trades by officers, directors and 10% owners, last 12 months.
| Traded | Insider | Type | Shares | Price | Value | Held after | Form 4 |
|---|---|---|---|---|---|---|---|
| 25 Feb 2026 | Debbane Raymond, Director | Purchase | 2,000 | $1.49 | $3.0K | 1,906,186 | 27 Feb 2026 |
| 23 Feb 2026 | Debbane Raymond, Director | Purchase | 100,000 | $1.47 | $147.0K | 1,904,186 | 25 Feb 2026 |
| 20 Feb 2026 | Debbane Raymond, Director | Purchase | 100,000 | $1.48 | $147.8K | 1,804,186 | 23 Feb 2026 |
| 19 Feb 2026 | Debbane Raymond, Director | Purchase | 50,000 | $1.44 | $72.0K | 1,704,186 | 23 Feb 2026 |
| 18 Feb 2026 | Debbane Raymond, Director | Purchase | 133,688 | $1.32 | $176.5K | 1,654,186 | 18 Feb 2026 |
| 17 Feb 2026 | Debbane Raymond, Director | Purchase | 76,857 | $1.31 | $100.5K | 1,520,498 | 18 Feb 2026 |
| 13 Feb 2026 | Debbane Raymond, Director | Purchase | 57,952 | $1.31 | $75.9K | 1,443,641 | 18 Feb 2026 |
| 2 Feb 2026 | Invus Global Management, Llc, Director | Purchase | 1,538,462 | $1.30 | $2.0M | 1,538,462 | 4 Feb 2026 |
Large holders
Schedule 13D and 13G filings by holders of more than 5% of the voting shares.
| Filed | Holder | Schedule | Stake | Shares |
|---|---|---|---|---|
| 6 Aug 2026 | FMR LLC | 13G amended | 11.7% | 51.8M |
| 8 May 2026 | Invus, L.P. | 13D amended | 39.4% | 175.2M |
| 2 Feb 2026 | Invus, L.P. | 13D amended | 36.2% | 154.7M |
Short interest
Shares sold short and not yet bought back, on each FINRA settlement date.
| Settlement | Shares short | Change | Days to cover |
|---|---|---|---|
| 15 Oct 2026 | 26.7M | +3.39% | 12.97 |
| 30 Sep 2026 | 25.8M | -10.3% | 6.16 |
| 15 Sep 2026 | 28.8M | -2.36% | 13.4 |
| 31 Aug 2026 | 29.5M | -9.95% | 10.28 |
| 14 Aug 2026 | 32.7M | -0.23% | 10.93 |
| 31 Jul 2026 | 32.8M | +0.29% | 12.46 |
| 15 Jul 2026 | 32.7M | +6.32% | 12.03 |
| 30 Jun 2026 | 30.8M | +21.08% | 4.44 |
Funds that hold it
From each fund's latest Form 13F.
180 funds held it at 30 Jun 2026: 80 added and 36 trimmed in the quarter. The largest:
| Fund | Shares | Value | Change in the quarter |
|---|---|---|---|
| Artal Group S.A. | 175,156,062 | $420.4M | +20,421,735 |
| FMR LLC | 51,782,045 | $124.3M | +6,725,707 |
| Siren, L.L.C. | 44,303,518 | $106.3M | 0 |
| Sessa Capital IM, L.P. | 18,960,836 | $45.5M | +1,047,875 |
| BlackRock, Inc. | 17,348,741 | $41.6M | +14,026,522 |
| Vanguard Capital Management LLC | 9,901,208 | $23.8M | +382,041 |
| Point72 Asset Management, L.P. | 8,251,325 | $19.8M | +436,719 |
| Geode Capital Management, LLC | 6,244,372 | $15.0M | +3,075,261 |
| State Street Corp. | 4,917,769 | $11.8M | +3,953,731 |
| Vanguard Portfolio Management LLC | 2,357,749 | $5.7M | +1,811,149 |
Peers
Companies in the same industry.
- Eli Lilly & Co. (LLY): revenue $86.5B, market value $1.29T
- Johnson & Johnson (JNJ): revenue $99.3B, market value $662.4B
- AbbVie Inc. (ABBV): revenue $64.4B, market value $513.9B
- Merck & Co., Inc. (MRK): revenue $66.6B, market value $361.0B
- Novartis AG (NVS): revenue $54.5B, market value $307.3B
- AstraZeneca PLC (AZN): revenue $58.7B, market value $270.6B
- Abbott Laboratories (ABT): revenue $46.6B, market value $180.9B
- Novo Nordisk A/S (NVO): revenue $46.8B, market value $174.8B
- Pfizer Inc. (PFE): revenue $63.7B, market value $170.7B
- Vertex Pharmaceuticals Inc. (VRTX): revenue $12.6B, market value $136.8B